Compare Intel Corp (INTC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Recursion Pharmaceuticals Inc — how do they compare? Intel Corp trades at $108.8 (market cap $566.04B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Intel Corp is far larger — about 264.5× Recursion Pharmaceuticals Inc's market cap, and Intel Corp pays a 2.24% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| INTC | RXRX | |
|---|---|---|
Market Cap | $566.04B | $2.14B |
Volume | 118,475,837 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $140.94 | $6.79 |
52-Week Low | $33.62 | $2.84 |
Typical Hold Time | 116 Days | 22 Days |
Enterprise Value | $586.85B | $1.66B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $113.12, up 0.55% today, with a bullish technical signal and recent earnings beats. The stock has surged over 220% in 2026, driven by AI momentum and foundry growth, though fundamentals show negative net income margins and elevated valuations. Cash flow improved in 2025, but revenue remains below 2022 peaks amid intense competition.
Outlook hinges on foundry turnaround execution; upside exists if Intel captures external customers for advanced nodes, but high debt and margin pressures pose risks. Analyst consensus is cautious with a $111.72 target, slightly below current price, reflecting skepticism on sustainability despite recent gains.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
